There were also imaginative and creative hypotheses on the use of existing dermatological drugs for the treatment of COVID-19 disease: omalizumab, montelukast, hydroxicloroquine (HCQ), apremilast, doxicicline, ivermective, anti-alpha 5 reductase agents, anti-IL-17, and endothelial receptor antagonists were all proposed as treatments for COVID-19. This evidence concerns the gene IL17A and COVID-19.